DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
2 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
3 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
4 Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies Visit Post
5 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
6 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
7 Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies Visit Post
8 Major Depressive Disorder Market Quadrant Growth Soars Owing to Expected Launch of Key Therapies Visit Post
9 Mounting Prevalence of Neurological Disorders and the Key Companies Bidding to Solve the Riddle Visit Post
10 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
11 The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market Visit Post
12 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
13 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
14 Neurovascular Thrombectomy Devices Market Visit Post
15 Vagus Nerve Stimulators Market Outlook Visit Post
16 Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products Visit Post
17 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
18 Does the use of Assistive Technologies in Autism Spectrum Disorder Payoff? Visit Post
19 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
20 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
21 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
22 Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation Visit Post
23 Spinal Stenosis Devices Market Size to Balloon Up Owing to Increasing Prevalence & Geriatric Population, as well as Medical Advancements Visit Post
24 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
25 Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape Visit Post
26 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
27 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
28 Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space Visit Post
29 Sleep Disorders: An Emerging Public Health Issue Visit Post
30 Kinase Inhibitors: Challenging the established Biologics as the new standard of care in autoimmune diseases? Visit Post
31 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
32 How Depression Is Eroding The Mental And The Physical Health Of The Society? Visit Post
33 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
34 Ever-Evolving Market Landscape of Transcatheter Aortic Valve Replacement Visit Post
35 How Will New Discoveries of Deep Brain Stimulation Devices Transform the Pharma Domain? Visit Post
36 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
37 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
38 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
39 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
40 Eating Disorders: What Happens When Stigma And Misconceptions Command The Health Visit Post
41 The Burden And The Impact Of Mental Health Issues In Today’s Time Visit Post
42 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
43 The Obesity Pandemic: What can we do about it? Visit Post
44 Parkinson's Disease: How close are we to a cure? Visit Post
45 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
46 Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market Visit Post
47 Top 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape Visit Post
48 21 of the most common questions about Epilepsy Visit Post
49 Treating Patients with Software: Digital Therapeutics Visit Post
50 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
51 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
52 Advancements in Neuromodulation Visit Post
53 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
54 Ever-evolving Market Dynamics of Epilepsy – a silver lining! Visit Post
55 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
56 The Growing Burden Of Neurodegenerative Disorders Visit Post
57 Cyclerion's olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche's gene therapy pact; RayzeBio debuts with $ 45M to target tumors Visit Post
58 Key Pharma Players Changing The Dynamics Of Schizophrenia Market Visit Post
59 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
60 How do we curb the Opioid Epidemic? Visit Post
61 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
62 J&J 's COVID-19 vaccine; Roche, AC Immune's anti-Tau Alzheimer's drug; Silverback nets $85 M; Anokion's deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development Visit Post
63 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
64 Roadblocks In The Peripheral Nerve Injury Market Require A Multi-faceted Approach Visit Post
65 The State of Alternative Medicine In The Healthcare Visit Post
66 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
67 Healthcare Delivery System: What lies in the future? Visit Post
68 The Rarity Of Dravet Syndrome: Challenges, and Treatments Visit Post
69 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
70 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
71 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
72 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
73 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
74 Medical Marijuana: Is it a blessing in disguise or a curse for humanity? Visit Post
75 Recognising The Warning Signs Of ADHD Visit Post
76 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
77 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
78 Addressing The Scattered Harbingers of Frontotemporal Dementia Visit Post
79 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
80 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
81 Can Alzheimer's be cured with Marijuana? Visit Post
82 Paradigm Shift In The Diabetic Peripheral Neuropathy Market Landscape As The Focus Shifts Towards The Cure Visit Post
83 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
84 How are Diabetic Peripheral Neuropathy medications changing the DPN market scenario? Visit Post
85 Can Aducanumab Slove the Puzzle Of Alzheimer’s? Visit Post
86 When Technological Innovations Help in Remembering for People Living with Alzheimer’s Visit Post
87 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
88 What are the 10 early signs of Alzheimer’s that are overlooked? Visit Post
89 An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario? Visit Post
90 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
91 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
92 Is the cure for Huntington’s disease on the horizon? Visit Post
93 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
94 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
95 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
96 Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial Visit Post
97 Dubai: A leading and exciting pharma hotspot Visit Post
98 Gene therapy might make cocaine less addictive Visit Post
99 Opioid Withdrawal Syndrome Pipeline: What lies in the future for those facing withdrawal symptoms Visit Post
100 US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing Visit Post
101 Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates Visit Post
102 Immune cells for age-related diseases; Regeneron's antibody for 2019-nCoV; FDA nods for hydrogel injection Visit Post
103 Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey Visit Post
104 Potential of Digital therapeutics and increasing CVDs Visit Post
105 Acceleron Pharma's drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson's disease Visit Post
106 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
107 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
108 Marijuana as a treatment approach Visit Post
109 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
110 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
111 Schizophrenia vs Bipolar disorder: Biomarkers to the rescue Visit Post
112 Increasing cases of Mania and Bipolar disorder market Visit Post
113 Fragile X Syndrome Market Visit Post
114 Alzheimer's Disease Market Infographic Visit Post
115 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
116 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
117 Complex Regional Pain Syndrome Upcoming Therapies Visit Post
118 Batten Disease Market: Barriers and Growth Opportunities Visit Post
119 GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre Visit Post
120 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
121 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
122 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
123 Chronic Lower Back Pain Market Analysis Visit Post
124 Chronic Lower Back Pain Therapy Market Visit Post
125 Chronic Lower Back Pain Visit Post
126 EMDR Therapy- Is it really that good? Visit Post
127 Notizia Visit Post
128 What is the link between Alzheimer's and Menopause? Visit Post
129 Lilly overtakes rivals with its Cluster Headache approval Visit Post
130 Antihypertensive drugs decrease Dementia rate Visit Post
131 World Multiple Sclerosis Day Visit Post
132 What is causing a rise in Autism rate? Visit Post
133 The Business Cocktail Visit Post
134 Autism Spectrum Disorder Visit Post
135 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
136 Notizia Visit Post
137 What can be the scope of Medical Marijuana? Visit Post
138 Notizia Visit Post
139 Boys are more likely to have autism! Visit Post
140 The Business Cocktail Visit Post
141 Alzheimer's drug fails! Is it time to move on? Visit Post
142 World Epilepsy Day Visit Post
143 EPILEPSY- A Neurological Disorder Visit Post
144 Complex regional pain syndrome (CRPS)-A debilitating disease Visit Post
145 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
146 Relation between gut microbes and depression bolstered Visit Post
147 Myasthenia Gravis Visit Post
148 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
149 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
150 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
151 Machine Learning Models to Help Predicting Cancer Symptoms, Plan Treatment Visit Post
152 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
153 ‘Transmissible’ Alzheimer’s theory gains traction Visit Post
154 Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal Visit Post
155 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
156 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
157 Notizia Visit Post
158 Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates Visit Post
159 Does coconut oil help prevent dementia? Visit Post
160 Notizia Visit Post
161 ‘Invisible’ mice reveal anatomical secrets Visit Post
162 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
163 Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives Visit Post
164 COMMERCIAL AND OTHERS Visit Post
165 KEY CLINICAL OUTCOMES Visit Post
166 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
167 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
168 Notizia Visit Post
169 Snippet Visit Post
170 Digital Pill: A new frontier in digital healthcare all set to take-off Visit Post
171 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
172 Voltage-Dependent T-Type Calcium Channel Blockers  Visit Post
173 Regulatory Visit Post
174 Snippet : Migraine Visit Post
175 Snippets : Parkinson Visit Post
176 Commercial Outcomes - Novartis Visit Post
177 Key Clinical Outcomes- 30/07/2018 Visit Post
178 Neuroscience Highlights - 17/07/2018 Visit Post
179 Notizia Visit Post
180 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential Visit Post
181 Hepatic Encephalopathy- An ailment of liver to brain Visit Post
182 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
183 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
184 Parkinson's and tuberculosis shares a common protein that could provide better drugs for both Visit Post
185 Business Cocktail Visit Post
186 Takeda buys Shire in a deal worth USD 62 billion Visit Post
187 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
188 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
189 Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment Visit Post
190 Hepatic Encephalopathy- Lack of active pipeline products Visit Post
191 Takeda acquisition on Shire raises its share by 25 percent Visit Post
192 Business Cocktail Visit Post
193 Business Cocktail Visit Post
194 NOTIZIA Visit Post
195 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
196 Spasticity Visit Post
197 Snippet Visit Post
198 NOTIZIA Visit Post
199 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
200 Business Cocktail Visit Post
201 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
202 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
203 Amyotrophic Lateral Sclerosis (ALS) a fatal disease! Visit Post
204 Business CockTail Visit Post
205 Cannabidiol trial; MyoKardia aims; LDL drug data Visit Post
206 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
207 Progressive Supranuclear Palsy– A neurodegenerative disorder Visit Post
208 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
209 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
210 Narcolepsy: Treatment options and market outlook Visit Post
211 Mylan closing Illinois plant; Insys spends $24M; Roche's Ocrevus; Greece’s corruption prosecutor quits Visit Post
212 Pfizer faces patent loss; Allergan over generics probe; Sun Pharma rallies Visit Post
213 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
214 FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat Visit Post
215 Can the brain detect Addictive cravings even after death? Visit Post
216 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
217 Obsessive-Compulsive Disorder: Emerging Therapies Visit Post
218 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
219 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
220 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
221 Nav1.7 Blockers- New Genre of Pain Relief Therapy Visit Post
222 Spinal Muscular Atrophy Emerging therapies Visit Post
223 Gene Therapy’s Emergence: The “New” approach for Huntington’s disease Visit Post